Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson to Sell Clontech in Q2 or Q3, Official Says; Buyer Remains Undisclosed

SAN FRANCISCO, Jan. 12 (GenomeWeb News) - Becton Dickinson expects to complete the sale of its Clontech division in the second or third quarter, the company said.

 

"The process is moving ahead according to schedule," Vince Forlenza, president of BD Biosciences, said at the JPMorgan Healthcare Conference, held here this week.

 

As GenomeWeb News reported last October, BD said it plans to sell the Clontech business because it wants to "focus its strategy on cell analysis, discovery labware and its new platforms of imaging and in vitro drug metabolism/toxicity testing," Edward Ludwig, chairman, president and CEO of BD said in a statement.

The planned sale "also allows us to direct our resources toward higher-growth opportunities in the pharmaceutical drug discovery arena," Ludwig added. BD has still not disclosed the buyer.

 

BD has hired Goldman Sachs to be its financial advisor for the divestiture.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.